Want to see SNWV full AI Analyst Report?
SNWV Stock Chart & Stats
$31.30
$1.30(5.42%)
At close: 4:00 PM EST
$31.30
$1.30(5.42%)
Day’s Range― - ―
52-Week Range$7.53 - $46.59
Previous CloseN/A
Volume17.14K
Average Volume (3M)78.76K
Market Cap
$100.44M
Enterprise Value$89.55M
Total Cash (Recent Filing)$10.78M
Total Debt (Recent Filing)$22.16M
Price to Earnings (P/E)6.6
Beta1.20
Next Earnings
Aug 18, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.76
Shares Outstanding8,598,976
10 Day Avg. Volume75,518
30 Day Avg. Volume78,757
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)157.84
Price to Sales (P/S)5.80
P/FCF Ratio132.13
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue2.02
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda3.95
Forecast
1Y Price Target
$47.00Price Target Upside50.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)$51.35M
Bulls Say, Bears Say
Bulls Say
Installed Base GrowthA growing installed base (net +90 systems to 1,382) indicates durable adoption of the dermaPACE platform. An expanding footprint increases future service and consumable demand, strengthens customer relationships, and supports longer-term revenue visibility from installed-system replacement and upgrade cycles.
Recurring Consumables TractionRising consumable usage (22% YoY) signals strengthening recurring revenue tied to each active system. Durable consumable demand smooths revenue volatility from capital sales, enhances lifetime customer value, and supports margin sustainability because ongoing usage generates repeat revenue independent of new unit placements.
Improved Cash GenerationPositive TTM operating and free cash flow indicates the business is converting improving earnings into cash, reducing reliance on external funding. Stronger cash generation paired with lower interest expense historically improves financing flexibility and supports reinvestment in commercial expansion and R&D over the medium term.
Bears Say
High Leverage / Thin EquityElevated leverage and a historically thin or negative equity cushion increase refinancing and solvency risk. Even with operational improvement, high debt relative to equity constrains strategic flexibility, raises interest sensitivity, and makes the company more vulnerable to cyclical setbacks or extended sales slowdowns.
CMS-Driven Market DisruptionRegulatory-driven reimbursement clawbacks have led to clinic closures and a used-equipment secondary market, structurally reducing near-term capital demand. This dynamic can persist across quarters, lengthening sales cycles, depressing new-unit placements, and forcing management to rely more on consumables recovery and accounts consolidation.
Profitability Volatility & ASP PressureShifts to reseller channels and one-time remediation costs compressed margins and produced negative GAAP EBITDA. Historical swings in profitability and revenue mix raise questions about earnings durability, meaning future margins may fluctuate with channel mix, large-account timing, and remediation or transition expenses.
Sanuwave Health News
SNWV FAQ
What was Sanuwave Health’s price range in the past 12 months?
Sanuwave Health lowest stock price was $7.53 and its highest was $46.59 in the past 12 months.
What is Sanuwave Health’s market cap?
Sanuwave Health’s market cap is $100.44M.
When is Sanuwave Health’s upcoming earnings report date?
Sanuwave Health’s upcoming earnings report date is Aug 18, 2026 which is in 36 days.
How were Sanuwave Health’s earnings last quarter?
Sanuwave Health released its earnings results on May 12, 2026. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.03.
Is Sanuwave Health overvalued?
According to Wall Street analysts Sanuwave Health’s price is currently Undervalued.
Does Sanuwave Health pay dividends?
Sanuwave Health does not currently pay dividends.
What is Sanuwave Health’s EPS estimate?
Sanuwave Health’s EPS estimate is -0.03.
How many shares outstanding does Sanuwave Health have?
Sanuwave Health has 8,598,976 shares outstanding.
What happened to Sanuwave Health’s price movement after its last earnings report?
Sanuwave Health reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went up 18.08%.
Which hedge fund is a major shareholder of Sanuwave Health?
Currently, no hedge funds are holding shares in SNWV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sanuwave Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.00 (50.16% Upside)
$47.00 (50.16% Upside)
Blogger Sentiment
Bullish
SNWV Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.00%
12-Months-Change
Fundamentals
Return on Equity
-450.56%
Trailing 12-Months
Asset Growth
20.23%
Trailing 12-Months
Company Description
Sanuwave Health
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. The company was founded on May 6, 2004 and is headquartered in Eden Prairie, MN.
SNWV Company Deck
SNWV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed cautious optimism: underlying demand signs and product adoption are improving (record applicator units, active systems growth, strong consumables usage, a growing large‑account pipeline, maintained full‑year guidance), but near‑term profitability metrics show pressure (gross margin compression, higher operating expenses, negative GAAP EBITDA) driven by reseller mix, one‑time remediation costs and market disruption from CMS actions. Management presents the issues as largely transitory and supported by a strengthening commercial pipeline.View all SNWV earnings summariesSNWV Stock 12 Month Forecast
Average Price Target
$47.00
▲(50.16% Upside)
Technical Analysis
Cerus
―
Senseonics Holdings
―
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Ownership Overview
21.99% Insiders
7.44% Mutual Funds
25.22% Other Institutional Investors
40.44% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---